Also known as Lys-Glu-Asp-Trp · KEDW tetrapeptide · Pancragen
Synthetic Lys-Glu-Asp-Trp tetrapeptide studied as a pancreas-tissue bioregulator.
Pancragen is a synthetic tetrapeptide (Lys-Glu-Asp-Trp) in the Khavinson short-peptide bioregulator series, studied for effects on pancreatic tissue and carbohydrate metabolism.
Pancragen (Lys-Glu-Asp-Trp) is the pancreas-directed member of the defined short-peptide bioregulator family, studied in the context of age-related metabolic and pancreatic decline in the originating research tradition.
Reported research examined markers of pancreatic function and carbohydrate metabolism in models, consistent with the class hypothesis of tissue-selective transcriptional modulation. Evidence is concentrated in one research tradition with limited independent replication, and it is not FDA-approved.
Proposed gene-regulatory modulation of pancreatic gene expression.
Behind every vial of Pancragen is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Pancragen, specifically, is brought into being.
On paper, Pancragen weighs in at roughly 576.6 daltons. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Assembling Pancragen means roughly 4 coupling cycles on the synthesizer — one protected residue added at a time, which is also 4 chances for an incomplete coupling to seed a deletion impurity. It is a short sequence, which makes the build comparatively tractable — but short does not mean trivial, and purity is still won or lost downstream.
The crude mixture — Pancragen plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one. It also contains oxidation-prone methionine or tryptophan residues, another family of impurities the chromatography has to resolve away.
A real batch of Pancragen proves itself: identity confirmed by mass spectrometry against its ~576.6 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Pancragen — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Producing Pancragen to a genuine purity spec means solid-phase synthesis, preparative HPLC purification, and batch quality control — none of it cheap, and none of it something you can verify by eye.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Pancragen is a synthetic Lys-Glu-Asp-Trp tetrapeptide studied as a pancreas-tissue bioregulator in the Khavinson short-peptide series.
The pancreas — each bioregulator in the series is framed around a specific target tissue.
It is concentrated in a single research tradition and is largely preclinical, so findings are preliminary. This page is a research and educational reference.
Dosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.